Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions
BLCL-RUX-FDA-01
Phase 1 other active
Quick answer
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions for No medical condition. is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- No medical condition.
- Phase
- Phase 1
- Modality
- other
- Status
- active